Background-We have previously shown that angiotensin II type 2 receptor (AT 2 R) stimulation causes endotheliumdependent vasodilation that does not desensitize after chronic angiotensin II type 1 receptor (AT 1 R) blockade, suggesting a role for AT 2 R in antihypertensive treatment.
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tion, 16 whereas in spontaneously hypertensive rats (SHR), flow (shear stress) stimulation of the endothelium is associated with an AT 1 R and endothelin-1 type A receptor activation, thus counteracting endothelium-dependent dilation. 17 Furthermore, acute administration of an AT 2 R inhibitor reversed both the acute antihypertensive effects and elevated level of bradykinin, NO, and cGMP in renal interstitial fluid caused by AT 1 R blockade in renal wrap and salt-restricted rats. 18, 19 Finally, we have recently shown the reproducibility of the vasodilator effect of AT 2 R stimulation under acute and chronic AT 1 R blockade, 20 further supporting the assumption that AT 2 R stimulation might play a role in the antihypertensive effect of AT 1 R-blocking drugs. Thus, we speculate that AT 2 R stimulation, and hence vasodilation, might play a role in antihypertensive treatments, especially when AT 1 Rblocking agents are used. Indeed, AT 1 R antagonists induce an important rise in circulating Ang II. AT 2 R might then be chronically overstimulated, participating in the maintenance of vasodilation, particularly because this effect was not easily desensitized. 20 Thus, in the present study we evaluated the vasomotor role of AT 2 R in resistance arteries isolated from SHR (hypertensive conditions) and after various chronic antihypertensive treatments, including ACE inhibition, AT 1 R blockade or a nonselective treatment, and AT 2 R expression and immunolocation. We hypothesized that AT 2 R-mediated dilation, which was impaired in untreated SHR, would be reestablished in mesenteric arteries taken from treated SHR in parallel with reductions in blood pressure.
Methods

Animal Model
Male WKY rats and SHR (aged 7 to 8 weeks) were separated into 8 groups receiving the following for 4 weeks in drinking water: WKY rats, placebo or AT 1 R antagonist (candesartan cilexetil; 2 mg/kg per day); SHR, placebo, ACE inhibitor (perindopril; 3 mg/kg per day), candesartan (2 mg/kg per day), nonselective antihypertensive drug (hydralazine; 2 groups: 16 or 24 mg/kg per day), or candesartan plus hydralazine (16 mg/kg per day).
The protocol used was in accordance with the European Community standards on the care and use of laboratory animals (authorization No. 00577).
Mean Arterial Pressure Measurement
After 4 weeks of treatment, rats were anesthetized with sodium pentobarbital (50 mg/kg IP). Mean arterial pressure (MAP) was measured in the right carotid artery with a catheter connected to a GOULD transducer and an analog-digital signal recording system (Biopac). 16, 17 
Isolated Mesenteric Artery
A 3-to 4-mm-long segment of mesenteric artery (205Ϯ11 m, internal diameter measured at 75 mm Hg in the absence of tone) was dissected, cannulated at both ends, and mounted in a videomonitored perfusion system, 21 as we have previously described. 16, 17, 20 Briefly, arteries were bathed in a physiological salt solution (PSS) maintained at 37°C, pH 7.4. The PO 2 was 160 mm Hg and the PCO 2 37 mm Hg. 16, 17, 20 The artery was superfused (4 mL/min), and flow through the vessel was maintained at a rate of 100 L/min, with intraluminal pressure set at 75 mm Hg. 20 Arterial diameter was measured (Living Systems Instrumentations) and recorded continuously (Biopac). Vessels were allowed to stabilize for at least 30 minutes before drugs were added to the PSS superfusion. The integrity of the endothelium was assessed by testing the relaxing effect of acetylcholine (1 mol/L) after precontraction with phenylephrine (1 mol/L). The arteries were then exposed to candesartan (100 nmol/L) for at least 30 minutes before exposure to Ang II while they were precontracted with phenylephrine (1 mol/L) and serotonin (0.1 mol/L) to induce a stable reduction in diameter. When this response had reached a plateau, a concentration-response curve to Ang II at 0.1 to 100 nmol/L or Ang II at 100 nmol/L was performed, and changes in diameter were measured. Acetylcholine (1 mol/L) was used to completely dilate the vessels. Eight rats were used in each group.
In separate series of experiments (nϭ5 per group), AT 2 R stimulation was repeated before and after application of one of the following drugs: the cyclooxygenase inhibitor indomethacin (10 mol/L), the thromboxane A 2 -PGH 2 receptor blocker SQ29548 (10 mol/L), the bradykinin B 2 receptor blocker HOE140 (0.1 mol/L), and the endothelin receptor blocker bosentan (10 mol/L).
Stimulation of AT 2 R was also performed before and after endothelium removal (5 seconds of air perfusion; nϭ4 rats per group) in WKY rats, untreated SHR, and SHR treated with candesartan plus hydralazine (16 mg/kg per day).
Western Blot Analysis of AT 2 R
Western blot analysis of AT 2 R was performed in mesenteric resistance arteries of WKY rats and SHR (nϭ8 per group). Mesenteric arteries were also isolated from SHR treated with hydralazine (24 mg/kg per day for 18, 23, or 48 days; nϭ5 per group) or with candesartan plus hydralazine (16 mg/kg per day; nϭ5 per group). Mesenteric arteries were homogenized with a lysis buffer (1% sodium dodecyl sulfate, 10 mmol/L Tris-HCl [pH 7.4], 1 mmol/L sodium orthovanadate, 2.5 mg/L leupeptin, and 5 mg/L aprotinin). Extracts were incubated at 25°C for 30 minutes and then centrifuged (1000g, 15 minutes, 14°C). Protein concentration was determined with the use of the Micro BCA Protein Assay Kit (Pierce). After denaturation at 100°C for 5 minutes, equal amounts of proteins (15 g) were loaded on a 9% polyacrylamide gel and transferred to nitrocellulose membranes for 12 hours (40 V, 4°C). Membranes were blocked with 10% BSA in TBST (20 mmol/L Tris [pH 8.0], 150 mmol/L NaCl, and 0.1% Tween-20) for 1 hour and were then incubated with AT 2 R rabbit polyclonal antibody (dilution 1:100, Santa Cruz) in washing solution at room temperature for 20 hours. The membranes were then washed and incubated with the anti-rabbit horseradish peroxidase antibody (dilution 1:5000; Amersham Pharmacia Biotech) for 1 hour at room temperature. After 3 washes with TBST, immunocomplexes were detected by chemiluminescent reaction (ECL kit; Amersham Pharmacia Biotech) with a computer-based imaging system (Fuji LAS 1000 Plus; Fuji Medical Systems). Quantification was performed by densitometric analysis.
Immunofluorescence Analysis of AT 2 R
Segments of mesenteric resistance arteries (nϭ6 rats per group) were mounted in embedding medium (Miles, Inc), frozen in isopentane precooled in liquid nitrogen, and stored at Ϫ80°C on transverse cross sections 7 m thick. Sections were incubated with candesartan (30 minutes, 10 nmol/L, 25°C), then with fluorescent Ang II (FITCbound Ang II, 30 minutes, 10 pmol/L, 25°C; Molecular Probes). Fluorescence staining was visualized by confocal microscopy (Biorad MRC-600). Control experiments were performed after incubation with nonfluorescent Ang II. Image analysis was performed with the use of Histolab (Microvision). Briefly, pixel quantification was performed after the media and the endothelial layer were separated. Data are given as percentage of control (with fluorescence in WKY rats taken as 100%).
Drugs
Candesartan cilexetil was kindly provided by AstraZeneca (Sweden). Other products were purchased from Sigma.
Statistical Analysis
Results are expressed as meanϮSEM. The significance of the different treatments was determined by ANOVA or 2-tailed Student paired t test. Probability values Ͻ0.05 were considered significant. Number of rats was used for the analysis. Figure 1 shows typical recordings obtained with mesenteric arteries isolated from WKY rats ( Figure 1A ) and SHR ( Figure 1B) . MAP was 118Ϯ8 mm Hg (nϭ8) in WKY rats and 183Ϯ11 mm Hg (nϭ8) in SHR. Isolated arteries were first incubated with candesartan (100 nmol/L, 30 minutes) and precontracted with phenylephrine (54Ϯ4 m diameter decrease). Addition of Ang II (100 nmol/L) induced a significant dilation (24Ϯ3 m diameter increase) in control WKY rats. By contrast, in SHR the stimulation of AT 2 R led to a significant contraction (8Ϯ3 m diameter decrease; Figure 1B ). In both WKY rats and SHR, the arteries were able to fully dilate when acetylcholine was added after Ang II. Diameter changes in response to AT 2 R stimulation (dilation in WKY rats or contraction in SHR) were suppressed by the AT 2 R antagonist PD123319 (1 mol/L). In the presence of candesartan and PD123319, Ang II produced no significant change in diameter (2Ϯ3 m, nϭ5 in WKY rats and Ϫ1Ϯ2 m, nϭ4 in SHR).
Results
MAP and AT 2 R-Mediated Dilation in Isolated Arteries
The contraction induced by Ang II (100 nmol/L) in arteries isolated from SHR was significantly reduced by indomethacin (10 mol/L; 6Ϯ2 versus 12Ϯ3 m reduction in diameter; nϭ5), SQ29548 (10 mol/L; 6Ϯ3 versus 14Ϯ3 m reduction in diameter; nϭ5) and by bosentan (10 mol/L; 7Ϯ3 versus 16Ϯ3 m reduction in diameter; nϭ5). The combination of indomethacin (10 mol/L) and bosentan (10 mol/L) suppressed Ang II-induced contraction in SHR (2Ϯ3 versus 14Ϯ3 m reduction in diameter; nϭ5). The bradykinin B 2 receptor blocker HOE140 (0.1 mol/L) did not significantly affect Ang II-induced contraction in SHR (13Ϯ3 versus 15Ϯ4 m reduction in diameter). In WKY rats, Ang IIinduced dilation was significantly reduced by N G -nitro-L-arginine methyl ester (L-NAME) (4Ϯ2 versus 24Ϯ4 m) and by HOE140 (6Ϯ3 versus 26Ϯ5 m).
The stimulation of AT 2 R produced a concentrationdependent dilation in arteries isolated from WKY rats and a concentration-dependent contraction in arteries isolated from SHR ( Figure 1C ; nϭ8 per group).
Concentration-dependent stimulation of AT 2 R (Ang II 0.01 to 100 nmol/L) was repeated in arteries isolated from WKY rats and SHR submitted to various treatments. Maximal responses to AT 2 R stimulation and MAP determined in the different groups are shown in Figure 2 .
There was no significant difference in MAP and AT 2 Rmediated dilation between control WKY rats (118Ϯ8 mm Hg; 24Ϯ3 m diameter increase; nϭ8) and WKY rats treated with candesartan (108Ϯ9 mm Hg; 19Ϯ5 m diameter increase; nϭ4).
In SHR, candesartan partly depressed MAP (146Ϯ8 mm Hg, nϭ4 versus 183Ϯ11 mm Hg, nϭ8; PϽ0.01 versus SHR and PϽ0.01 versus WKY rats) and tended to reduce AT 2 R-mediated contraction, although this did not reach significance (8Ϯ3 versus 3Ϯ2 m diameter decrease).
In SHR, treatment with perindopril reduced MAP (nϭ4; 125Ϯ6 mm Hg; PϽ0.01), and AT 2 R stimulation induced a significant vasodilation (6Ϯ2 m diameter increase) that was significantly lower than AT 2 -induced dilation in WKY rats.
In SHR treated with hydralazine (16 mg/kg per day; nϭ4), MAP decreased to a level that was still higher than in WKY rats (145Ϯ11 mm Hg; nϭ6; PϽ0.01 versus SHR and PϽ0.05 versus WKY rats), and stimulation of AT 2 R induced vasoconstriction (3Ϯ1 m diameter decrease; nϭ6).
In SHR treated with a higher dose of hydralazine (24 mg/kg per day; nϭ4), MAP was reduced to a normal value (105Ϯ10 mm Hg; PϭNS versus WKY rats), and AT 2 R induced a significant vasodilation (27Ϯ7 m diameter increase; PϭNS versus WKY rats).
In SHR treated with candesartan plus hydralazine (16 mg/kg per day), MAP was reduced to a normal level (nϭ4; 102Ϯ9 mm Hg; PϭNS versus WKY rats), and AT 2 R induced a significant vasodilation (22Ϯ5 m diameter increase; PϭNS versus WKY rats).
Endothelium removal did not affect AT 2 R-dependent contraction in untreated SHR (12Ϯ3 m with endothelium versus 14Ϯ3 m contraction without endothelium; nϭ4). On the other hand, AT 2 R-dependent dilation was abolished by endothelium removal in both untreated WKY rats (24Ϯ4 versus 3Ϯ2 m dilation; nϭ4) and SHR treated with candesartan plus hydralazine (16 mg/kg per day; 26Ϯ4 versus 4Ϯ2 m increase in diameter; nϭ4).
Western Blot Analysis of AT 2 R
In resistance arteries isolated from untreated WKY (nϭ8) rats and untreated SHR (nϭ8), as well as from SHR treated with hydralazine alone (24 mg/kg per day; nϭ5) or hydralazine (16 mg/kg per day; nϭ5) combined with candesartan, AT 2 R expression was quantified. Western blot analysis showed that AT 2 R was significantly less expressed in SHR than in WKY rats (46%) in isolated mesenteric resistance arteries ( Figure  3 ). Hydralazine (24 mg/kg per day) gradually raised AT 2 R expression in SHR treated for 18, 23, and 48 days. After 48 days, AT 2 R expression was significantly higher than in SHR, but it remained significantly lower than in WKY rats (70%; Figure 3 ). However, after 44 days of treatment, candesartan plus hydralazine (16 mg/kg per day) restored AT 2 R expression in SHR to a level equivalent to that found in WKY rats (96.7% versus 100%; Figure 3 ).
Immunohistology Analysis of AT 2 R
In WKY rats, immunofluorescence analysis of mesenteric resistance arteries, with the use of confocal microscopy, indicated that AT 2 R was present in the endothelium, in the smooth muscle, and in the adventitia. In the endothelium, AT 2 R immunofluorescence was lower in SHR than in WKY rats (5Ϯ3% of WKY; PϭNS; nϭ6 per group). In the media a significant fluorescence could be detected, although it was lower than in WKY rats (32Ϯ6%; PϽ0.01; nϭ6). In SHR treated with candesartan plus hydralazine (16 mg/kg per day), immunofluorescence of AT 2 R was restored to a level equivalent to that found in WKY rats (compared with WKY rats: 88Ϯ11% in the endothelium and 81Ϯ18% in the media) ( Figure 4 ).
Discussion
The present study demonstrates that AT 2 R stimulation induced a vasoconstriction in untreated SHR resistance arteries associated with a decrease in AT 2 R expression. Specific or nonspecific antihypertensive treatments restored AT 2 R expression and its vasodilator function when the decrease in pressure was sufficient.
Recent evidence suggests that AT 2 R stimulation causes vasodilation in small resistance arteries in normotensive rats. 6, 7, 11, 16, 17, 20, 22 This vasodilation may play an important role in the regulation of arterial blood pressure by increasing the diameter of resistance arteries. Vasodilation induced by AT 2 R stimulation has been described in several vascular territories and is usually associated with NO production by endothelial cells and cGMP production by smooth muscle cells. 23 In some but not all arteries investigated, bradykinin B 2 receptor activation is involved in AT 2 R-dependent dilation. 9 -11,22 Importantly, AT 2 R-mediated dilation does not desensitize, in contrast to AT 1 R-dependent contraction, supporting the assumption that AT 2 R dilation might have a role in the treatment of hypertension. 20, 24 Furthermore, in agreement with previous studies, 21,25 AT 2 R was found in resistance arteries by Western blot and RT-PCR analysis. With the use of immunofluorescence, AT 2 R was localized in endothelial and smooth muscle cells, as in previous studies in rat mesenteric arteries 16 and skeletal muscle arterioles. 26 We found that AT 2 R stimulation in SHR induced a vasoconstriction, in agreement with previous studies showing that in young hypertensive rats Ang II-induced contraction was decreased by AT 2 R blockade. 25 Interestingly, this effect involved stimulation of endothelin-1 and probably thromboxane A 2 . We found that AT 2 R expression was lower in SHR resistance arteries than in WKY rats. However, a decreased expression cannot readily explain a reversal of dilation into contraction. The mechanism of this reversal remains to be discovered but may involve a switch in signaling from constrictor to dilator mechanisms due to increased endothelial AT 2 R expression. Indeed, our immunohistological analysis of AT 2 R in mesenteric arteries from SHR showed undetectable AT 2 R labeling in the endothelium that was reestablished with antihypertensive treatment that normalized blood pressure. In addition, AT 2 R-dependent contraction in SHR is not affected by endothelium removal, whereas AT 2 R-dependent dilation is abolished in the absence of endothelium. Thus, the difference in the type of response might reflect a change in AT 2 R expression between the endothelium and the smooth muscle. Nevertheless, because of the small size of the resistance arteries, AT 2 R expression and mRNA level were not significantly decreased by endothelium removal in either SHR or WKY rats (D. Henrion, unpublished data). In addition, cultured endothelial cells rapidly lose AT 2 R phenotype, thus preventing a study of AT 2 R expression in cultured endothelial cells from WKY rats or SHR.
Stimulation of the NO-cGMP pathway by AT 2 R has been shown initially in aortic cells. 27 In the dog coronary circulation, NO production by Ang II is activated through both AT 1 R and AT 2 R stimulation. 28 Other evidence suggests that AT 1 R and AT 2 R may not always oppose each other, at least with regard to NO production. 23 In the mesenteric circulation, we found that AT 2 R-dependent flow-mediated dilation requires NO production and that exogenous stimulation of AT 2 R in the same arteries produces dilation. 16 In WKY rats, candesartan did not significantly change MAP, and AT 2 R-mediated dilation was preserved, as we have previously reported. 20 By contrast, candesartan partly decreased MAP and AT 2 R-mediated vasoconstriction in SHR. Similarly, low-dose hydralazine, also partly reducing MAP, inhibited AT 2 R-mediated vasoconstriction. Obviously, these treatments were not able to normalize MAP and to restore AT 2 R vasodilator function. Indeed, it was only when MAP was sufficiently reduced in SHR that AT 2 R-mediated vasodilation was observed. First, with the use of an ACE inhibitor, MAP was decreased to a level similar to that observed in WKY rats. In this case, stimulation of AT 2 R induced vasodilation. A further decrease in MAP, with the use of a higher dose of hydralazine or candesartan plus hydralazine, was also associated with a vasodilator effect of AT 2 R stimulation.
Interestingly, the different groups studied allowed a correlation to be drawn between MAP and the type and amplitude of the response to AT 2 R stimulation ( Figure 2 ). Thus, from high to low MAP, AT 2 R stimulation moved progressively from contraction to dilation. In addition, this effect was associated with a different AT 2 R expression. In SHR, AT 2 R expression was low in the wall of mesenteric arteries compared with WKY. After MAP reduction in SHR, AT 2 R expression was restored to the level of WKY rats. However, it is difficult to determine whether AT 2 R-mediated dilation is a cause or a consequence of the reduction in blood pressure. In the combined candesartan/hydralazine group of SHR, the time course for AT 2 R expression, assessed by Western blots, was in parallel with the restoration of maximal AT 2 Rmediated dilation and normotension, which may indicate a primary role for AT 2 R. On the other hand, equivalent reductions in MAP caused by hydralazine were associated with maximal AT 2 R-mediated dilation despite suppressed AT 2 R expression. These discrepancies in AT 2 R abundance between treatments may reflect distinct AT 2 R locations within the vasculature. Indeed, more precise immunohistological analysis demonstrated that AT 2 R expression was located in the endothelial and smooth muscle cells in WKY rats, whereas in SHR AT 2 R was not detectable in the endothelium. On the other hand, in SHR treated with candesartan plus hydralazine, MAP was restored, AT 2 R stimulation induced vasodilation, and AT 2 R expression was equivalent to that found in WKY rats. In this group, immunohistology of AT 2 R showed the presence of the receptor in both endothelia and smooth muscle cells. Thus, we can speculate that the presence or absence of AT 2 R on endothelial cells has a key role in determining the type of response, at least in part because the inhibition of the vasodilation in WKY rats by L-NAME does not uncover a vasoconstriction due to receptors located on the muscle, as revealed by immunohistology. We can also assume that MAP per se is the effector determining the type of response induced by AT 2 R stimulation ( Figure 2C ).
In conclusion, in resistance arteries of SHR, (1) AT 2 R is downregulated by hypertension, and (2) specific and nonspecific antihypertensive treatments restore AT 2 R expression and vasodilator functions. Whether or not this AT 2 R plasticity directly contributes to the blood pressure reduction, this AT 2 R dilator mechanism is likely to contribute to the maintenance of a vasodilator state during chronic treatment.
